

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

50-818

APPROVAL LETTER



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 50-818

NDA APPROVAL

Alcon, Inc.
Alcon Research, Ltd.
Attention: C. Brad Wooldridge, M.S.
Associate Director, Regulatory Affairs
6201 South Freeway
Fort Worth, TX 76134-2099

Dear Mr. Wooldridge:

Please refer to your new drug application (NDA) dated June 14, 2007, received June 15, 2007, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for TobraDex ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05%.

This application is subject to the exemption provisions in section 125 (d)(2) of Title I of the FDA Modernization Act of 1997.

We acknowledge receipt of your submissions dated May 12 (two), June 2, 10, and 20, August 14, September 8, and 22 (two), October 21, and December 5 and 22, 2008, and January 15, 22 and February 3, 6, and 10, 2009.

The August 14, 2008, submission constituted a complete response to our April 15, 2008, action letter.

This new drug application provides for the use of TobraDex ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format submitted on February 10, 2009.

We acknowledge your February 10, 2009, submission containing carton and container labels. Please submit final printed label carton and container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (October 2005)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on

heavy-weight paper or similar material. For administrative purposes, designate this submission **"Final Printed Carton and Container Labels for approved NDA 50-818."** Approval submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration
Center for Drug Evaluation
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see www.fda.gov/cder/ddmac

Please submit one market package of the drug product when it is available.

If you issue a letter communicating important safety related information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDA 50-818

Page 3

If you have any questions, call Raphael R. Rodriguez, Regulatory Project Manager, at (301) 796-0798.

Sincerely,

{See appended electronic signature page}

Wiley A. Chambers, M.D.
Acting Director
Division of Anti-Infective and
Ophthalmology Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Wiley Chambers
2/13/2009 02:12:54 PM